Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

NCT03919175 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT03919175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03919175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Terminated
Start date
September 1, 2019
Completion date
May 5, 2024
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, follicular lymphoma grade 2, follicular lymphoma grade iiia, follicular lymphoma, grade 1, lymphoma, marginal zone b cell lymphoma, marginal zone lymphoma